drugset / Trial / NCT03397095

Sequential Treatment of Extra-Corporeal Shock Wave Combined With aUtologous Bone marRow Mesenchymal Stem Cells on Patients With ischEmic Heart Disease : the S-CURE Study

NCT03397095

Phase 1/2 Unknown 120 enrolled Shanghai 10th People's Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to evaluate the efficacy, safety and tolerability of autologous bone marrow derived mesenchymal stem cells compared to placebo (sham operation) when administered via percutaneous coronary infusion to patients with ischemic heart disease, who are screened by D-SPECT and have pretreated with 3-month cardiac shock wave therapy.

Timeline

Start
2018-04-03
Primary completion
2019-12-01
Completion
2022-04-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject BM-MSCs Cell therapy 1e+06 cells/kg Other

Indications